Structure via PubChem · Public domain (PubChem)
カプレオマイシン
Sign in to saveAlso known as Capastat sulfate, Ogostal, Capromycin
Capreomycin is an antibiotic which is given in combination with other antibiotics for the treatment of tuberculosis. Specifically it is a second line treatment used for active drug resistant tuberculosis. It is given by injection into a vein or muscle.
OverviewAI-generated
Capreomycin is a chemical substance identified by the NCI Thesaurus ID C72607. It is indexed in PubMed, where a query for the term yields 823 results.
In the PubChem database, capreomycin is assigned the CID 135483770. Its InChIKey is VCOPTHOUUNAYKQ-WBTCAYNUSA-N. The molecule has a topological polar surface area (TPSA) of 737. It contains 27 hydrogen bond donors and 23 hydrogen bond acceptors.
Synthesized by Vinony from 8 facts across 3 sources: Wikidata, PubMed, PubChem. Generated from structured data (not the Wikipedia text) and checked against those facts — may still contain errors.
Key facts
- Drug.image
- Capreomycin IA.svg
- Drug.image_class
- skin-invert-image
- Drug.image2
- Capreomycin IB.svg
- Drug.image_class2
- skin-invert-image
- Drug.tradename
- Capastat
- Drug.MedlinePlus
- a682860
- Drug.routes_of_administration
- Intramuscular
- Drug.ATC_prefix
- J04
- Drug.ATC_suffix
- AB30
- Drug.CAS_number
- 11003-38-6
- Drug.PubChem
- 3000502
- Drug.DrugBank
- DB00314
- Drug.ChemSpiderID
- 2272094
- Drug.UNII
- 232HYX66HC
- Drug.KEGG
- D07607
- Drug.ChEMBL
- 2221250
- Drug.NIAID_ChemDB
- 007653
- Drug.IUPAC_name
- (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide; (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-3,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide | C=25 | H=44 | N=14 | O=8 | SMILES = C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCN=C(N2)N)CNC(=O)C[C@H](CCCN)N.C1CN=C(N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N | StdInChI = 1S/C25H44N14O8.C25H44N14O7/c26-4-1-2-11(27)6-17(41)32-8-14-20(43)35-15(9-34-25(30)47)21(44)39-18(13-3-5-31-24(29)38-13)23(46)33-7-12(28)19(42)37-16(10-40)22(45)36-14;1-11-19(41)36-15(9-32-17(40)7-12(27)3-2-5-26)21(43)37-16(10-34-25(30)46)22(44)39-18(14-4-6-31-24(29)38-14)23(45)33-8-13(28)20(42)35-11/h9,11-14,16,18,40H,1-8,10,26-28H2,(H,32,41)(H,33,46)(H,35,43)(H,36,45)(H,37,42)(H,39,44)(H3,29,31,38)(H3,30,34,47);10-15,18H,2-9,26-28H2,1H3,(H,32,40)(H,33,45)(H,35,42)(H,36,41)(H,37,43)(H,39,44)(H3,29,31,38)(H3,30,34,46)/b15-9+;16-10+/t11-,12-,13+,14-,16-,18-;11-,12-,13-,14+,15-,18-/m00/s1 | StdInChIKey = VCOPTHOUUNAYKQ-WBTCAYNUSA-N | density = | density_notes = | melting_point = | melting_high = | melting_notes = | boiling_point = | boiling_notes = | solubility = | sol_units = | specific_rotation =
via Wikipedia infobox
Chemical data
- Formula
- C50H88N28O15
- Molecular weight
- 1321.4 g/mol
- IUPAC name
- (3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3S)-3,6-diamino-N-[[(2S,5S,8E,11S,15S)-15-amino-11-[(4R)-2-amino-1,4,5,6-tetrahydropyrimidin-4-yl]-8-[(carbamoylamino)methylidene]-2-methyl-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide
- SMILES
- C[C@H]1C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N[C@H](C(=O)NC[C@@H](C(=O)N1)N)[C@H]2CCNC(=N2)N)CNC(=O)C[C@H](CCCN)N.C1CNC(=N[C@H]1[C@H]2C(=O)NC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N/C(=C/NC(=O)N)/C(=O)N2)CNC(=O)C[C@H](CCCN)N)CO)N)N
- InChIKey
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N
- Polar surface area
- 737 Ų
- H-bond donors
- 27
- H-bond acceptors
- 23
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Molecule type
- Small molecule
via ChEMBL · EBI
Research
823 papers- Capreomycin.2006
- Capreomycin.2012
- Capreomycin.Tuberculosis (Edinburgh, Scotland) · 2008
- Capreomycin.Journal of clinical pathology · 1967
- Aminoglycosides and Capreomycin in the Treatment of Multidrug-resistant Tuberculosis: Individual Patient Data Meta-analysis of 12 030 Patients From 25 Countries, 2009-2016.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2021
via PubMed
Wikidata facts
- Instance of
- essential medicine
Show 4 more facts
- NCI Thesaurus ID
- C72607
- defined daily dose
- 1
- medical condition treated
- tuberculosis
- natural product of taxon
- Streptomyces
via Wikidata · CC0
Article · 日本語
カプレオマイシン(Capreomycin)は結核の治療に用いられる抗生物質であり、他の抗生物質と組み合わせて使用される。具体的には活性の二次治療に用いられる。投与法は点滴静脈注射または筋肉注射である。 一般的な副作用は腎臓の不具合、難聴、平衡感覚の衰え、穿刺による痛みがあげられる。その他の副作用は麻痺による呼吸困難である。ストレプトマイシンまたはその他の視聴覚神経に損害を与える可能性のある薬との併用は推奨されない。妊娠中の患者への投与は胎児の腎臓または聴覚に問題を引き起こす恐れがあるため推奨されない。カプレオマイシンは一般的にアミノグリコシド系抗生物質に属する医薬品である。その作用機序は不明確である。 カプレオマイシンは1960年代にストレプトマイセス属から発見された。世界保健機関の必須医薬品リストに掲載されており、最も効果的で安全な医療制度に必要とされる医薬品である。開発途上国での卸値は1投与約$6.25～$8.98米ドルである。
Abstract from DBpedia / Wikipedia · CC BY-SA